The FDA has approved a fixed combination of daunorubicin and cytarabine (Vyxeos) for the treatment of newly diagnosed therapy-related acute myeloid leukemia (AML) as well as AML with myelodysplasia-related changes.
The US Food and Drug Administration has approved the tyrosine kinase inhibitor ibrutinib (Imbruvica) for adult patients with chronic graft vs host disease who have failed on one or more lines of prior systemic therapy.
The FDA has approved enasidenib (Idhifa) for the treatment of relapsed or refractory IDH2-mutant acute myeloid leukemia.
Dose optimization of nilotinib is feasible and may help patients with chronic-phase chronic myeloid leukemia achieve molecular responses, according to results of a new study.
A lower dose of rabbit anti–T-lymphocyte globulin was superior to a higher dose in children with hematologic malignancies undergoing transplant from an unrelated donor.
The FDA has approved the marketing of a new lab test used with flow cytometry to aid in the detection of several types of hematologic malignancies.
Treatment with imatinib results in good overall survival in patients with chronic myeloid leukemia, approaching a normal life expectancy, according to the CML-IV study.
The FDA has granted priority review status for two new indications of dasatinib (Sprycel), according to the drug’s developer.
Treatment of adult relapsed or refractory acute lymphoblastic leukemia with inotuzumab ozogamicin was associated with increased hepatotoxicity, especially after follow-up hematopoietic stem cell transplantation.
The FDA placed a clinical hold on three trials of the PD-1 inhibitor pembrolizumab in combination with pomalidomide or lenalidomide for patients with multiple myeloma.